Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
Atopic Dermatitis

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-severe Atopic Dermatitis (STREAM-AD)

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-severe Atopic Dermatitis (STREAM-AD)
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-severe Atopic Dermatitis (STREAM-AD) Scan and Download Back

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.